This open-label trial (n=20) seeks to evaluate psilocybin-assisted interpersonal social and rhythm therapy (IPSRT) for treatment-resistant depression. Participants will receive two doses of psilocybin and eight sessions of psychotherapy.
IPSRT aims to minimize disruptions to daily routines and rhythms since these changes can lead to disrupted sleep and an unstable mood in some people.
Primary outcome measures include the feasibility of delivering this type of therapy in combination with psilocybin as well as the feasibility of recruiting patients with major depression for this treatment in New Zealand.
Topic Depression
Compound Psilocybin
Country New Zealand
Visit trial
Status
Not yet recruiting
Results Published
No
Start date
15 November 2022
End date
30 November 2023
Chance of happening
79%
Phase
Phase I
Design
Open
Type
Interventional
Generation
First
Participants
20
Sex
All
Age
21- 75
Therapy
Yes
Trial Details
This is a single-arm, open-label interventional study of psilocybin-assisted interpersonal and social rhythm therapy for treatment-resistant depression. 20 participants will be recruited to take part in this 8-week intervention that involves 8 sessions of psychotherapy and 2 doses of psilocybin.NCT Number NCT05581797
Measures Used
Hamilton Depression Rating ScaleThe Hamilton Depression Rating Scale (HDRS) is a multiple item questionnaire used to provide an indication of depression, and as a guide to evaluating recovery. The scale consists of 17 items which each item being scoring on a 3 or 5 point scale. The higher the score, the more likely a person is depressed.